6. ALTERNATE PROCEDURES OR TREATMENTS: The eligibility rule for this study 
limits subjects to people who have already been through conventional therapy 
(such as surgery or external beam radiation therapy), and those for whom no 
other therapy is feasible. Therefore, the only alternatives would be other clinical 
research studies or no specific antitumor treatment. Of course, standard 
supportive care will be given regardless of participation in therapy. 
Permission for Autopsy: It is anticipated that permission to perform an autopsy 
will be requested in the event of a patient's death following participation in this 
study. Accurate determination of the cause of death is of vital importance to 
future patients. 
UNDERSTANDING OF PARTICIPANTS 
7. I have been given an opportunity to ask any questions concerning the procedure 
involved and the investigator has been willing to reply to my inquiries. This 
procedure will be administered under the above numbered, titled and described 
clinical research protocol at this institution. I hereby authorize Dr. Jack A. Roth, 
the attending physician/investigator, and designated associates to administer the 
treatment. 
8. I have been told and understand that my participation in this clinical research 
study is voluntary. I am free not to participate or to withdraw my consent and 
discontinue my participation at any time. Such action will not result in any 
penalty or loss of benefits to which I may otherwise be entitled, and I will 
continue to receive treatment by my physician at this institution. 
If I am considering not participating in this research or withdrawing my consent 
and stopping participation, I have been advised that I should first discuss with 
my physician the potential consequences of such a decision. 
In addition, I understand that the investigator may discontinue the clinical 
research study if, in the sole opinion and discretion of the investigator, the study 
or treatment offers me little or no future benefit, or the supply of medication 
ceases to be available or other causes prevent continuation of the clinical 
research study. The investigator will notify me should such circumstances arise 
and my physician will advise me about available treatments which may be of 
benefit at that time. 
I will be informed of any new findings developed during the course of this clinical 
research study which may relate to my willingness to continue participation in 
the study. 
Recombinant DNA Research, Volume 19 
[293] 
